Effects of atorvatatin in N-terminal pro-brain natriuretic peptide plasma levels in hypercholesterolemic patients with or without hypertension;Efecto de la atorvastatina sobre los valores del propéptido natriurético cerebral N-terminal en pacientes con hipercolesterolemia con hipertensión arterial y sin ella

Medicina Clinica

Volumn 127, Issue 14, 2006, Pages 521-525

  Muñoz Torrero, Juan Francisco Sánchez ^a,b   Crespo Rincón, Leandro ^a   Fernández Pereira, Luis ^a   Agustín Herrero, Juan ^a   Pereira Navarro, Gema ^a   Cámara Hijón, Carmen ^a   Torres Pérez, Fernando ^a   Costo Campoamor, Alberto ^a  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^b NONE   (Spain)

Author keywords

Hypercholesterolemia; Hypertension; NT proBNP

Indexed keywords

ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; NITRIC ACID; NITRIC ACID DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 33751249317     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13093721     Document Type: Article

References (28)

1. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology. 1993;132:1961.
2. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide: a new marker of cardiac impairment. Clin Endocrinol. 1997;47:287-96.
3. Rademaker MT, Richards AM. Cardiac natriuretic peptides for cardiac health. Clin Sci. 2005; 108:23-36.
4. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-63.
5. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666-70. Disponible en: http://roche-diagnostic. us/press_ room/2006/010306.htm
6. Packard CJ. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440-5.
7. Sacks FM, Pfeffer MA, Moye LA, Rouleau JF, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-9.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart diseases: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344;1383-9.
9. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3 methylglutaryl coenzime A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 21:1712-9.
10. Gómez-Fernández P. Estatinas y efectos beneficiosos. Med Clin (Barc). 2005;125:578-9.
11. Ashton E, Liew D, Krum H. Should patients with chronic heart failure be treated with «statins»? Heart Fail Monit. 2003;3:82-6.
12. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol. 2004;93: 1124-9.
13. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure. Circulation. 2005;112:357-63.
14. Grundy SM, Cleeman JI, Merz NB, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;44:720-32.
15. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21:1011-53.
16. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47.
17. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107:2786-92.
18. Omland T, Richards AM, Wergeland R, Vick-Mo H. B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease. Am J Cardiol. 2005;95:24-8.
19. McKie PM, Burnett JC. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc. 2005; 80:1029-36.
20. Sayama H, Nakamura Y, Saito N, Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coron Artery Dis. 1999;10:537-40.
21. D'Souza SP, Baxter GF. B-type natriuretic peptide: a good omen in myocardial ischaemia? Heart. 2003;89:707-9.
22. Goetze JP, Gore A, Moller CH, Steinbruchei DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J. 2004;15:1928-30.
23. Chong AY, Blann AD, Patel J, Freestone B, Lip GY. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation. 2004;110:1794-8.
24. Nomura H, Hayashi T, Esaki T, Hattori A, Kano-Hayashi H, Iguchi A. Standardization of plasma brain natriuretic peptide concentrations in older Japanese - relationship to latent renal dysfunction and ischemic heart disease. J Am Geriatr Soc. 2002;50:1504-9.
25. Hostetter TH. Chronic kidney disease predicts cardiovascular disease. N Engl J Med. 2004; 351:1344-6.
26. Wierzbicki AS. Lipid lowering: another method of reducing blood pressure? J Hum Hypertens. 2002;11:753-60.
27. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91-7.
28. Kinlay S. Potential vascular benefits of statins. Am J Med. 2005;118:62S-7S.